I believe I've found the answer.
ama-assn.org
This has been the case with the agent AR177, a short (17-mer) G-T-containing polynucleotide that inhibits both purified integrase and the replication of HIV in cultured cells. In fact, this blocking of HIV in cells was so substantial that a clinical trial of AR177 (Zintevir, Anorex Pharmaceuticals, The Woodlands, Tex), said to be the first test of an integrase inhibitor, was initiated in early 1998. However, it has since been shown that whereas AR177 may inhibit purified integrase in the laboratory, that is almost certainly not how the agent blocks the replication of HIV in living cells. Rather, AR177 appears to prevent the binding of gp120, HIV's surface protein, to CD4 cells. |
